Yazar "Sevindik, Omur Gokmen" seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study(Galenos Yayincilik, 2019) Ciftciler, Rafiye; Sevindik, Omur Gokmen; Tekgunduz, Ali Irfan Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagul; Payzn, Bahriye; Dogu, Mehmet Hilmi; Karakus, Volkan; Altuntas, Fevzi; Buyukasik, Yahya; Demirkan, FatihObjective: Significant developments occurred in the clinical management of acute lymphoblastic leukemia (ALL) in adults in recent decades. However, treatment results are still not satisfactory, especially in routine practice. The objective of this study was to evaluate the general clinical features, treatment details, and outcomes of a large group of patients followed in multiple centers in Turkey with a diagnosis of ALL. Materials and Methods: A retrospective analysis of the data of patients with ALL was made, the patients having been diagnosed and treated between January 2003 and June 2017 by different protocols in the hematology clinics of ten different centers. A total of 288 patients, aged between 17 and 76 years old, were included in the study. In this retrospective multicenter analysis of patients with ALL, classification of patients was performed based on treatment period, Philadelphia chromosome positivity, treatment regimen, and administration of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: The majority of cases were B-cell in origin, while 224 patients had B-ALL and 64 of the patients had T-ALL. Median follow-up duration for all patients was 18.2 months (range: 0.03-161 months). Philadelphia chromosome positivity was determined in 49 patients (21.9%), and 54 patients (18.8%) were receiving allo-HSCT. After induction chemotherapy, 219 patients (76.0%) achieved complete remission, 32 patients (11.2%) were evaluated as treatment refractory, and 37 patients (12.8%) were deceased. Median overall survival was 47.7 months (95% confidence interval: 36.1-59.2) and median disease-free survival was 23.4 months (95% confidence interval: 6.7-40.0) for all patients. Conclusion: Multicenter studies are extremely important for defining the specific clinical features of a particular disease. The results of this study will make a significant contribution to the literature as they reflect real-life data providing valuable information about the Turkish ALL patient profile.Öğe A Case Series of CML Patients Who Were Presented with Isolated Thrombocytosis(Amer Soc Hematology, 2022) Karakus, Volkan; Aslan, Vedat; Parca, Guleycan; Sevindik, Omur Gokmen; Karadag, Fatma Keklik; Kurtoglu, Erdal; Saydam, Guray[No abstract available]Öğe Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience(Galenos Yayincilik, 2015) Ozdemirkiran, Fusun; Payzin, Bahriye; Kiper, H. Demet; Kabukcu, Sibel; Cagliyan, Gulsum Akgun; Kahraman, Selda; Sevindik, Omur Gokmen; Ceylan, Cengiz; Kadikoylu, Gurhan; Sahin, Fahri; Keskin, Ali; Arslan, Oyku; Ozcan, Mehmet Ali; Gorgun, Gulnur; Bolaman, Zahit; Buyukkececi, Filiz; Bilgir, Oktay; Alacactoglu, Inci; Vura, Filiz; Tombuloglu, Murat; Gokgoz, Zafer; Saydam, GürayObjective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists, which came into use in recent years, seem to be an effective option in the treatment of resistant cases. This study aimed to retrospectively assess the efficacy, long-term safety, and tolerability of eltrombopag in Turkish patients with chronic ITP in the Aegean region of Turkey. Materials and Methods: Retrospective data of 40 patients with refractory ITP who were treated with eltrombopag in the Aegean region were examined and evaluated. Results: The total rate of response was 87%, and the median duration of response defined as the number of the platelets being over 50x10(9)/L was 19.5 (interquartile range: 5-60) days. In one patient, venous sinus thrombosis was observed with no other additional risk factors due to or related to thrombosis. Another patient with complete response and irregular follow-up for 12 months was lost due to sudden death as the result of probable acute myocardial infarction. Conclusion: Although the responses to eltrombopag were satisfactory, patients need to be monitored closely for overshooting platelet counts as well as thromboembolic events.Öğe An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy(Cig Media Group, Lp, 2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke[No Abstract Available]Öğe An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy(Amer Soc Hematology, 2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke[No Abstract Available]Öğe Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience(Wiley, 2018) Gemici, Aliihsan; Aydogdu, Ismet; Terzi, Hatice; Sencan, Mehmet; Aslan, Alma; Kaya, Ali Hakan; Dal, Mehmet Sinan; Akay, Meltem Olga; Dogu, Mehmet Hilmi; Ayyildiz, Orhan; Sahin, Fahri; Cagliyan, Gulsum Akgun; Yilmaz, Mehmet; Gokgoz, Zafer; Bilen, Yusuf; Demir, Cengiz; Sevindik, Omur Gokmen; Korkmaz, Serdal; Eser, Bulent; Altuntas, FevziNodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma. In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey. We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty-three patients were included in the study. Median age of patients was 37.5years (18-70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow-up was 46months. During follow-up, none of the patients died. Seven patients relapsed or progressed after initial therapy at a median of 12months. Five of 7 relapsed/refractory patients (71.4%) were salvaged with chemotherapy only (DHAP, ICE), and the remaining 2 (28.6%) were salvaged with chemoimmunotherapy. All of relapsed/refractory patients were able to achieve complete remission after salvage therapy. Lactate dehydrogenase levels were significantly higher in patients with progressive disease compared with nonprogressive disease. Our study showed an excellent outcome with all patients alive at last contact with a median follow up of 46months despite a wide range of different therapeutic approaches. All relapsed and refractory patients were successfully salvaged despite a low frequency of patients received immunotherapy in conjunction with chemotherapy. Our results suggest that immunotherapy may be reserved for further relapses.Öğe Turkish Acute Lymphoblastic Leukemia Registry, Retrospective Phase Data(Amer Soc Hematology, 2019) Demirkan, Fatih; Ciftciler, Rafiye; Sevindik, Omur Gokmen; Tekgunduz, Emre; Erkurt, Mehmet Ali; Vural, Filiz; Karakus, Volkan[No Abstract Available]Öğe The Turkish experience with therapeutic plasma exchange: A national survey(Pergamon-Elsevier Science Ltd, 2019) Korkmaz, Serdal; Medeni, Serife Solmaz; Demirkan, Fatih; Besisik, Sevgi Kalayoglu; Dadin, Senem Altay; Cagliyan, Gulsum Akgun; Hacioglu, Sibel Kabukcu; Sari, Ismail; Sahin, Deniz Goren; Arat, Mutlu; Dagdas, Simten; Ozet, Gulsum; Kutlu, Nermin; Akyol, Tulay Karaagac; Ozcebe, Osman Ilhami; Teke, Hava Uskudar; Unal, Demet Kiper; Guner, Naile; Tombak, Anil; Celik, Halil; Bay, Ilker; Kiki, Ilhami; Ozgur, Gokhan; Erkurt, Mehmet Ali; Ozatli, Duzgun; Meletli, Ozgur; Demircioglu, Sinan; Demir, Cengiz; Kurtoglu, Erdal; Vural, Filiz; Tobu, Mahmut; Karakus, Abdullah; Ayyildiz, Orhan; Dal, Mehmet Sinan; Ozturk, Berna Afacan; Albayrak, Murat; Ocakci, Serkan; Bolaman, Zahit; Sonmez, Mehmet; Karakus, Volkan; Sevindik, Omur Gokmen; Berber, Ilhami; Dogu, Mehmet Hilmi; Gulturk, Emine; Ulas, Turgay; Payzin, Bahriye; Kuku, Irfan; Cagirgan, Seckin; Altuntas, FevziTherapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE.
